{
  "pmcid": "9291605",
  "abstract": "1. A 250-word version\n\nTitle: Randomised Controlled Trial of Hydroxyethyl Starch vs. Albumin in Cardiac Surgery\n\nBackground: The safety of third-generation hydroxyethyl starch (HES) solutions in cardiac surgery is uncertain. We aimed to assess whether intra-operative HES administration affects postoperative kidney function and haemostasis compared to human albumin.\n\nMethods: This single-centre, triple-blinded, parallel-group, randomised, non-inferiority trial was conducted at the Cleveland Clinic. We enrolled patients aged 40â€“85 scheduled for elective aortic valve replacement, with or without coronary artery bypass grafting, between June 2015 and February 2018. Participants were randomised 1:1 to receive 6% HES 130/0.4 or 5% human albumin. Randomisation was done using a secure web-based system, and allocation was concealed. The primary outcome was urinary neutrophil gelatinase-associated lipocalin (NGAL) concentrations measured at baseline, 1 hour, and 24 hours post-surgery.\n\nResults: A total of 141 patients were analysed (69 HES, 72 albumin). Postoperative NGAL was slightly lower with HES (median 5 ng/ml) vs. albumin (median 5 ng/ml), but not non-inferior [ratio of geometric means 0.91, 95% CI 0.57 to 1.44; p = 0.15]. Nine of 11 coagulation measures were non-inferior. No significant adverse events were reported.\n\nInterpretation: HES administration during cardiac surgery showed similar effects on kidney function and haemostasis compared to albumin, but variability precluded non-inferiority conclusions. Long-term outcomes were similar between groups.\n\nTrial registration: NCTXXXXX\n\nFunding: Supported by [Funding Source].",
  "word_count": 222
}